$VRSK

Is VRSK Worth Buying as Recurring Revenue Battles a Premium Valuation?

Verisk Analytics (VRSK) reported Q2 2026 revenues of $806.3 million, up 4.3% YoY, with adjusted EPS of $1.98 (+5.3%) and adjusted EBITDA of $463.6 million (+4.2%). Subscription revenue was 83% of sales. Deferred revenue rose to $573.9 million. The article notes VRSK trades at 21.7x forward earnings versus peer averages near 18x, and highlights higher debt and expenses.

Original reporting
Published Aug 13, 2026, 2:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 11:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is VRSK Worth Buying as Recurring Revenue Battles a Premium Valuation? — source image
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

Trader takeaway is a valuation risk check: subscription visibility and cash generation are positives, but higher debt service costs and expense growth raise execution risk at a premium multiple.

02

Market read

Provides concrete operating and balance-sheet datapoints for VRSK and frames them against forward earnings valuation, informing whether the premium is justified.

03

What to watch

The article highlights deferred revenue and cash conversion, but does not quantify churn, renewal rates, or competitive displacement risk, which could matter more than the headline subscription mix.

Relevance 4/10Novelty 4/10Timing: published mid-August, framing a buy/hold decision around Q2 2026 operating metrics and forward multiple

Background

The piece evaluates Verisk’s recurring revenue durability versus its forward valuation premium, using Q2 2026 subscription and cash-flow metrics.

Company-level read

Ticker impact

$VRSKNeutralMedium confidence
Context

Verisk reports Q2 2026 subscription mix at 83% of revenue, plus higher deferred revenue and cash flow, while discussing its forward valuation premium.

Expected impact

Near-term price impact is likely limited because the piece is primarily an investment thesis around disclosed operating metrics and valuation, not a new catalyst.

Evidence & confidence

It provides concrete datapoints (subscription share, deferred revenue, OCF/FCF, debt and net interest, expense growth) but does not introduce a fresh event like guidance, a deal, or a regulatory action.

Market effects

Reinforces the market narrative that insurance data/analytics firms with subscription models can sustain premium multiples, but leverage and cost growth can cap upside.

No clear regional transmission beyond US-listed insurance analytics sentiment.

Limited, as the discussion is company-specific and does not cite global regulatory or macro shocks.

Counterpoint

A premium multiple may already price in durability; if net interest expense and SG&A/legal costs keep rising, the valuation cushion could compress even with steady subscription growth.

Key entities

  • Verisk Analytics, Inc.

    Subject of the article, discussed via Q2 2026 subscription mix, deferred revenue, cash flow, debt, and valuation premium.

  • Guidewire Software, Inc.

    Mentioned as a peer example in property and casualty software/analytics, without new company-specific news.

  • CCC Intelligent Solutions Holdings Inc.

    Mentioned as a peer example in cloud/data/AI for insurance workflows, without new company-specific news.

Related articles

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer

$VRSKMed

Verisk Told It Can't Abandon $2.35B AccuLynx Deal

Delaware Chancery Court ruled that Verisk Analytics Inc. improperly exited its $2.35 billion acquisition of AccuLynx, according to the court. The decision requires Verisk to proceed with the deal, affecting the timing and terms of the insurance data and software transaction for investors.

$VRSKMed

Why is Verisk Analytics stock sliding today?

Verisk Analytics shares fell 5.6% after the Delaware Chancery Court ruled Verisk must proceed with its $2.35 billion AccuLynx acquisition. The court said Verisk’s conduct invalidated its Dec 2025 deal termination and awarded AccuLynx damages plus interest. Verisk said it strongly disagrees and is evaluating next steps, including a possible appeal, while FTC antitrust review remains unresolved.

$VRSKMedAI 8/10

Verisk stock falls after court rejects $2.35B merger termination

Verisk Analytics (NASDAQ:VRSK) shares fell about 5.5% after a Delaware Chancery Court rejected Verisk’s bid to terminate its $2.35B acquisition of AccuLynx. The court said Verisk’s termination was invalid and AccuLynx is owed damages for direct costs plus interest. Verisk said it strongly disagrees and is evaluating options, including an appeal.

$VRSKMedAI 8/10

Verisk Slides as Court Revives AccuLynx Deal Fight

Verisk Analytics (VRSK) fell about 5% as a Delaware Court of Chancery ruling revived its dispute over the terminated AccuLynx acquisition. Verisk agreed to buy AccuLynx in July 2025 and terminated in Dec. 2025. The court required Verisk to pursue regulatory approval efforts for the $2.35 billion deal. Verisk reported Q2 2026 revenue of $806 million.